Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis

A Dagnew; O Ilhan; W Lee; Zoster 039 Study Group; M Sinisalo

doi:10.1016/S1473-3099(19)30163-X

Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis

A Dagnew
, O Ilhan
, W Lee
, Zoster 039 Study Group
, M Sinisalo

Research output: Contribution to journal › Article › Scientific › peer-review

236 Citations (Scopus)

Original language	English
Pages (from-to)	988-1000
Journal	The Lancet Infectious Diseases
Volume	19
Issue number	9
DOIs	https://doi.org/10.1016/S1473-3099(19)30163-X
Publication status	Published - 2019
Publication type	A1 Journal article-refereed

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Publication forum classification

Publication forum level 3

Access to Document

10.1016/S1473-3099(19)30163-X

Cite this

@article{7d0855e39b874b89902fa14baf949dca,

title = "Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis",

author = "A Dagnew and O Ilhan and W Lee and \{Zoster 039 Study Group\} and M Sinisalo",

year = "2019",

doi = "10.1016/S1473-3099(19)30163-X",

language = "English",

volume = "19",

pages = "988--1000",

journal = "The Lancet Infectious Diseases",

issn = "1473-3099",

publisher = "Elsevier",

number = "9",

}

Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis. / Dagnew, A; Ilhan, O; Lee, W et al.
In: The Lancet Infectious Diseases, Vol. 19, No. 9, 2019, p. 988-1000.

Research output: Contribution to journal › Article › Scientific › peer-review

TY - JOUR

T1 - Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis

AU - Dagnew, A

AU - Ilhan, O

AU - Lee, W

AU - Zoster 039 Study Group

AU - Sinisalo, M

PY - 2019

Y1 - 2019

U2 - 10.1016/S1473-3099(19)30163-X

DO - 10.1016/S1473-3099(19)30163-X

M3 - Article

SN - 1473-3099

VL - 19

SP - 988

EP - 1000

JO - The Lancet Infectious Diseases

JF - The Lancet Infectious Diseases

IS - 9

ER -